207 related articles for article (PubMed ID: 33684965)
1. Systematic inhibitor selectivity between PARP1 and PARP2 enzymes: Molecular implications for ovarian cancer personalized therapy.
Zuo X; Zhao H; Li D
J Mol Recognit; 2021 Jul; 34(7):e2891. PubMed ID: 33684965
[TBL] [Abstract][Full Text] [Related]
2. Poly (ADP-Ribose) Polymerases (PARPs) and PARP Inhibitor-Targeted Therapeutics.
Li N; Wang Y; Deng W; Lin SH
Anticancer Agents Med Chem; 2019; 19(2):206-212. PubMed ID: 30417796
[TBL] [Abstract][Full Text] [Related]
3. HPF1 completes the PARP active site for DNA damage-induced ADP-ribosylation.
Suskiewicz MJ; Zobel F; Ogden TEH; Fontana P; Ariza A; Yang JC; Zhu K; Bracken L; Hawthorne WJ; Ahel D; Neuhaus D; Ahel I
Nature; 2020 Mar; 579(7800):598-602. PubMed ID: 32028527
[TBL] [Abstract][Full Text] [Related]
4. Serine-linked PARP1 auto-modification controls PARP inhibitor response.
Prokhorova E; Zobel F; Smith R; Zentout S; Gibbs-Seymour I; Schützenhofer K; Peters A; Groslambert J; Zorzini V; Agnew T; Brognard J; Nielsen ML; Ahel D; Huet S; Suskiewicz MJ; Ahel I
Nat Commun; 2021 Jul; 12(1):4055. PubMed ID: 34210965
[TBL] [Abstract][Full Text] [Related]
5. Leveraging shape screening and molecular dynamics simulations to optimize PARP1-Specific chemo/radio-potentiators for antitumor drug design.
Khizer H; Maryam A; Ansari A; Ahmad MS; Khalid RR
Arch Biochem Biophys; 2024 Jun; 756():110010. PubMed ID: 38642632
[TBL] [Abstract][Full Text] [Related]
6. Crystal structure of the catalytic domain of human PARP2 in complex with PARP inhibitor ABT-888.
Karlberg T; Hammarström M; Schütz P; Svensson L; Schüler H
Biochemistry; 2010 Feb; 49(6):1056-8. PubMed ID: 20092359
[TBL] [Abstract][Full Text] [Related]
7. PARP Power: A Structural Perspective on PARP1, PARP2, and PARP3 in DNA Damage Repair and Nucleosome Remodelling.
van Beek L; McClay É; Patel S; Schimpl M; Spagnolo L; Maia de Oliveira T
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34066057
[TBL] [Abstract][Full Text] [Related]
8. Novel inhibitors of poly(ADP-ribose) polymerase/PARP1 and PARP2 identified using a cell-based screen in yeast.
Perkins E; Sun D; Nguyen A; Tulac S; Francesco M; Tavana H; Nguyen H; Tugendreich S; Barthmaier P; Couto J; Yeh E; Thode S; Jarnagin K; Jain A; Morgans D; Melese T
Cancer Res; 2001 May; 61(10):4175-83. PubMed ID: 11358842
[TBL] [Abstract][Full Text] [Related]
9. Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-
Johannes JW; Balazs A; Barratt D; Bista M; Chuba MD; Cosulich S; Critchlow SE; Degorce SL; Di Fruscia P; Edmondson SD; Embrey K; Fawell S; Ghosh A; Gill SJ; Gunnarsson A; Hande SM; Heightman TD; Hemsley P; Illuzzi G; Lane J; Larner C; Leo E; Liu L; Madin A; Martin S; McWilliams L; O'Connor MJ; Orme JP; Pachl F; Packer MJ; Pei X; Pike A; Schimpl M; She H; Staniszewska AD; Talbot V; Underwood E; Varnes JG; Xue L; Yao T; Zhang K; Zhang AX; Zheng X
J Med Chem; 2021 Oct; 64(19):14498-14512. PubMed ID: 34570508
[TBL] [Abstract][Full Text] [Related]
10. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
Liu FW; Tewari KS
Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
[TBL] [Abstract][Full Text] [Related]
11. Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.
Zhou Q; Ji M; Zhou J; Jin J; Xue N; Chen J; Xu B; Chen X
Biochem Pharmacol; 2016 May; 107():29-40. PubMed ID: 26920250
[TBL] [Abstract][Full Text] [Related]
12. Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.
Thorsell AG; Ekblad T; Karlberg T; Löw M; Pinto AF; Trésaugues L; Moche M; Cohen MS; Schüler H
J Med Chem; 2017 Feb; 60(4):1262-1271. PubMed ID: 28001384
[TBL] [Abstract][Full Text] [Related]
13. Contrasting sirtuin and poly(ADP-ribose)polymerase activities of selected 2,4,6-trisubstituted benzimidazoles.
Yeong KY; Tan SC; Mai CW; Leong CO; Chung FF; Lee YK; Chee CF; Abdul Rahman N
Chem Biol Drug Des; 2018 Jan; 91(1):213-219. PubMed ID: 28719017
[TBL] [Abstract][Full Text] [Related]
14. Revisiting PARP2 and PARP1 trapping through quantitative live-cell imaging.
Zhang H; Lin X; Zha S
Biochem Soc Trans; 2022 Aug; 50(4):1169-1177. PubMed ID: 35959996
[TBL] [Abstract][Full Text] [Related]
15. Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update.
Jain PG; Patel BD
Eur J Med Chem; 2019 Mar; 165():198-215. PubMed ID: 30684797
[TBL] [Abstract][Full Text] [Related]
16. Structural basis for the inhibition of poly(ADP-ribose) polymerases 1 and 2 by BMN 673, a potent inhibitor derived from dihydropyridophthalazinone.
Aoyagi-Scharber M; Gardberg AS; Yip BK; Wang B; Shen Y; Fitzpatrick PA
Acta Crystallogr F Struct Biol Commun; 2014 Sep; 70(Pt 9):1143-9. PubMed ID: 25195882
[TBL] [Abstract][Full Text] [Related]
17. Development of Next-Generation Poly(ADP-Ribose) Polymerase 1-Selective Inhibitors.
Ngoi NYL; Leo E; O'Connor MJ; Yap TA
Cancer J; 2021 Nov-Dec 01; 27(6):521-528. PubMed ID: 34904816
[TBL] [Abstract][Full Text] [Related]
18. Free energy calculation provides insight into the action mechanism of selective PARP-1 inhibitor.
Cao R
J Mol Model; 2016 Apr; 22(4):74. PubMed ID: 26969680
[TBL] [Abstract][Full Text] [Related]
19. Mortaparib, a novel dual inhibitor of mortalin and PARP1, is a potential drug candidate for ovarian and cervical cancers.
Putri JF; Bhargava P; Dhanjal JK; Yaguchi T; Sundar D; Kaul SC; Wadhwa R
J Exp Clin Cancer Res; 2019 Dec; 38(1):499. PubMed ID: 31856867
[TBL] [Abstract][Full Text] [Related]
20. Common and unique genetic interactions of the poly(ADP-ribose) polymerases PARP1 and PARP2 with DNA double-strand break repair pathways.
Ghosh R; Roy S; Kamyab J; Danzter F; Franco S
DNA Repair (Amst); 2016 Sep; 45():56-62. PubMed ID: 27373144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
